Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Linamarin is a naturally occurring cyanogenic glycoside found in plants such as cassava (*Manihot esculenta*), flax, and lima beans. It serves as a chemical defense mechanism; upon tissue damage, it is hydrolyzed by the enzyme linamarase (a beta-glucosidase) to release toxic hydrogen cyanide (HCN). In biomedical research, linamarin is being investigated as a pro-drug for targeted cancer therapy, particularly in Gene-Directed Enzyme Prodrug Therapy (GDEPT). In this approach, the linamarase gene is delivered to tumor cells to locally activate linamarin into cyanide, which then inhibits cellular respiration and induces apoptosis. Recent studies have explored its potential against glioblastoma and cervical cancer, including its ability to bind and inhibit the HPV16 E6 oncoprotein.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on linamarin.